Brean Murray Carret & Co. Downgrades Ardea Biosciences (RDEA) to Hold; AstraZeneca (AZN) Steps In

April 23, 2012 9:54 AM EDT
Get Alerts RDEA Hot Sheet
Price: $31.96 --0%

Rating Summary:
    6 Buy, 7 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Brean Murray Carret & Co. downgraded Ardea Biosciences (NASDAQ: RDEA) from Buy to Hold with a price target of $40.00.

Analyst, Jonathan Aschoff, said, "Ardea announced AstraZeneca (NYSE: AZN) has made a bid of $32 per share for RDEA, and that both have unanimously approved the agreement. Ardea also reported that about 30% of the shareholder votes have been cast in favor of the agreement, and therefore we believe that this acquisition will go through. We are downgrading RDEA to Hold, based on the limited remaining upside from now til the transaction has closed."

For an analyst ratings summary and ratings history on Ardea Biosciences click here. For more ratings news on Ardea Biosciences click here.

Shares of Ardea Biosciences closed at $20.84 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades, Mergers and Acquisitions

Related Entities

Brean Murray Carret & Co.